Controversial pre-clinical and human studies reported that both up- and downregulation of the AMPK/SIRTs/PGC1α network can lead to glycolytic reprogramming and HCC [174], thereby making it mandatory to focus research efforts to elucidate discrepancies. This evidence concerns the gene PPARGC1A and hepatocellular carcinoma.